Intravenous administration of CP-4055 (ELACYT™) in patients with solid tumours. A phase I study

References

• Francis SO, Mahlberg MJ, Johnson KR, Ming ME, Dellavalle RP. Melanoma chemoprevention. J Am Acad Dermatol 2006; 55: 849–61
   PubMed Web of Science ®Google Scholar
• Gogas HJ, Kirkwood JM, Sondak VK. Chemotherapy for metastatic melanoma: Time for a change?. Cancer 2007; 109: 455–64
   PubMed Web of Science ®Google Scholar
• Kasper B, D'Hondt V, Vereecken P, Awada A. Novel treatment strategies for malignant melanoma: A new beginning?. Crit Rev Oncol Hematol 2007; 62: 16–22
   PubMed Web of Science ®Google Scholar
• Chan JK, Cheung MK, Husain A, Teng NN, West D, Whittemore AS, et al. Patterns and progress in ovarian cancer over 14 years. Obstet Gynecol 2006; 108: 521–8
   PubMed Web of Science ®Google Scholar
• Herzog TJ, Pothuri B. Ovarian cancer: A focus on management of recurrent disease. Nat Clin Pract Oncol 2006; 3: 604–11
   PubMedGoogle Scholar
• Colombo N, Van Gorp T, Parma G, Amant F, Gatta G, Sessa C, et al. Ovarian cancer. Crit Rev Oncol Hematol 2006; 60: 159–79
   PubMed Web of Science ®Google Scholar
• Subramanian J, Govindan R. Lung cancer in never smokers: A review. J Clin Oncol 2007; 25: 561–70
   PubMed Web of Science ®Google Scholar
• Juergens RA, Brahmer JR. Adjuvant treatment in non-small cell lung cancer. Where are we now?. J Natl Compr Canc Netw 2006; 4: 595–600
   PubMedGoogle Scholar
• Lister TA, Rohatiner AZ, Bassan R, Gregory W, Willis L, Barnett MJ, et al. Conventional dose cytosine arabinoside in combination chemotherapy for acute myelogenous leukaemia. Semin Oncol 1987; 14: 53–4
   PubMedGoogle Scholar
• Bolwell BJ, Cassileth PA, Gale RP. High dose cytarabine: A review. Leukaemia 1988; 2: 253–60
   PubMed Web of Science ®Google Scholar
• Plunkett W, Gandhi V. Cellular pharmacodynamics of anticancer drugs. Semin Oncol 1993; 20: 50–63
   PubMed Web of Science ®Google Scholar
• Rustum YM, Raymakers RA. 1-Beta-arabinofuranosylcytosine in therapy of leukaemia: Preclinical and clinical overview. Pharmacol Ther 1992; 56: 307–21
   PubMed Web of Science ®Google Scholar
• Grant S. Ara-C: Cellular and molecular pharmacology. Adv Cancer Res 1998; 72: 197–233
   PubMed Web of Science ®Google Scholar
• Gailani S, Nussbaum A. Correlation of response to 1-beta-D-arabinofuranosyl cytosine and metabolism of drug by tumour. J Med 1976; 7: 93–102
   PubMedGoogle Scholar
• Bajetta E, Verusio C, Bonfante V, Bonadonna G. Cytarabine and cisplatin in advanced malignant melanoma. Cancer Treat Rep 1986; 70: 1441–2
   PubMedGoogle Scholar
• Chabner BA. Anticancer drugs. Cancer: Principles and Practice of Oncology4^th ed, VT DeVita, S Hellman, SA Rosenberg. JB Lippincott Co, Philadelphia 1993; 365–369
   Google Scholar
• Someya H, Waud WR, Parker WB. Long intracellular retention of 4’-thio-arabinofuranosylcytosine 5’-triphosphate as a critical factor for the antisolid tumour activity of 4’-thio-arabinofuranosylcytosine. Cancer Chemother Pharmacol 2006; 57: 772–80
   PubMedGoogle Scholar
• Breistøl K, Balzarini J, Sandvold ML, Myhren F, Martinsen M, De Clercq F, et al. Antitumour activity of P-4055 (Elaidic Acid-Cytarabine) compared to cytarabine in metastatic and s.c. human tumour xenograft models. Cancer Res 1999; 59: 2944–9
   PubMed Web of Science ®Google Scholar
• Ross DD, Chen SR, Cuddy DP. Effects of 1-beta-D-arabinofuranosylcytosine on DNA replication intermediates monitored by PH-step alkaline elution. Cancer Res 1990; 50: 2658–66
   PubMed Web of Science ®Google Scholar
• Bergman AM, Kuiper CM, Voorn DA, Comijn EM, Myhren F, Sandvold ML, et al. Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinofuranosylcytosine in leukaemia and solid tumour cell lines. Biochem Pharmacol 2004; 67: 503–11
   PubMed Web of Science ®Google Scholar
• Bergman AM, Kuiper CM, Myhren F, Sandvold ML, Hendriks HR, Peters GJ. Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinosylcytosine (ara-C) in leukaemia and solid tumour cell lines. Nucleosides Nucleotides Nucleic Acids 2004; 23: 1523–6
   PubMed Web of Science ®Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumours. J Natl Cancer Inst 2000; 92: 205–16
   PubMed Web of Science ®Google Scholar
• Delaunoit T, Raymond E, Awada A, Savinelli F, Culine S, Rasch W, et al A three schedule phase I trial of CP-4055, weekly and q2 weeks in patients with advanced or metastatic solid tumors. J Clin Oncol 2006;(Suppl): 2067 (abstract).
   Google Scholar
• Stentoft J. The toxicity of cytarabine. Drug Safety 1990; 5: 7–27
   PubMed Web of Science ®Google Scholar
• Peters WG, Colly LP, Willemze R. High-dose cytosine arabinoside: Pharmacological and clinical aspects. Blut 1988; 56: 1–11
   PubMedGoogle Scholar
• Herzig RH, Wolff SN, Lazarus HM, Phillips GL, Karanes C, Herzig GP. High-dose cytosine arabinoside therapy for refractory leukaemia. Blood 1983; 62: 361–9
   PubMed Web of Science ®Google Scholar
• Capizzi RL, White JC, Powel BL, Perrino F. Effect of dose on the pharmacokinetic and pharmacodynamic effects of cytarabine. Semin Hematol 1991; 28: 54–69
   PubMed Web of Science ®Google Scholar